{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T07:59:51Z","timestamp":1742803191434},"reference-count":0,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Rev"],"abstract":"<jats:p>MicroRNA-9 (MiR-9) dysregulation has been observed in various cancers. Recently, MiR-9 is considered to have a part in hematopoiesis and hematologic malignancies. However, its importance in blood neoplasms is not yet well defined. Thus, this study was conducted in order to assess the significance of MiR-9 role in the development of hematologic neoplasia, prognosis, and treatment approaches. We have shown that a large number of MiR-9 targets (such as FOXOs, SIRT1, CCND1, ID2, CCNG1, Ets, and NFkB) play essential roles in leukemogenesis and that it is overexpressed in different leukemias. Our findings indicated MiR-9 downregulation in a majority of leukemias. However, its overexpression was reported in patients with dysregulated MiR-9 controlling factors (such as MLLr). Additionally, prognostic value of MiR-9 has been reported in some types of leukemia. This study generally emphasizes on the critical role of MiR-9 in hematologic malignancies as a prognostic factor and a therapeutic target.<\/jats:p>","DOI":"10.4081\/oncol.2018.348","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T11:47:59Z","timestamp":1522151279000},"source":"Crossref","is-referenced-by-count":5,"title":["The impact of Mir-9 regulation in normal and malignant hematopoiesis"],"prefix":"10.3389","author":[{"given":"Abbas","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaban","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsalan","family":"Jalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Shirzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najmaldin","family":"Saki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,27]]},"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.oncologyreviews.org\/index.php\/or\/article\/download\/348\/330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.oncologyreviews.org\/index.php\/or\/article\/download\/348\/345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.oncologyreviews.org\/index.php\/or\/article\/download\/348\/330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T11:25:28Z","timestamp":1663241128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.4081\/oncol.2018.348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.4081\/oncol.2018.348","relation":{},"ISSN":["1970-5565","1970-5557"],"issn-type":[{"value":"1970-5565","type":"electronic"},{"value":"1970-5557","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3,27]]}}}